Skip to main content

Mesoblast (ASX:MSB) logo Mesoblast Health Care
Biopharmaceuticals Cancer Medicine Oncology

$1.14 -0.01 (-0.44%)

High

$1.17

Low

$1.13

Trades

1,304

Turnover

$2,983,889

Volume

2,606,681
30 June 2023 at 4:10pm
Register to track MSB and receive email alerts.

Short Interest

ASIC data, 9 Sep 2026

% Shorted

7.27% 0.03
vs 7.24% prior report

Most Shorted Rank

35th
of 689 shorted ASX stocks

Peak Short

11.00%
Oct 2015

Days to Cover

31.7
at 50d avg vol
View full short position history →
Subject
MediaBot
MSB Article: ASX tumbles to three-month low; ASX CHESS outage

MediaBot
MSB Article: ASX plummets to six-week low in broad sell-off

MediaBot
MSB Article: ASX slips as tech declines; Mesoblast soars 47pc

MediaBot
MSB Article: Mesoblast surges on FDA ‘rare paediatric disease’ designation

MediaBot
MSB Article: ASX rebounds as Whitehaven, Mesoblast power up

MediaBot
MSB Article: ASX rebounds as Whitehaven, Mesoblast power up

MediaBot
MSB Article: Mesoblast taps Bell Potter for $98m equity raising

MediaBot
MSB Article: ASX closes higher but ends the week down 1pc

MediaBot
MSB Article: Mesoblast: the biotech that hasn’t – yet

MediaBot
MSB Article: ASX ends the session higher but posts first weekly loss in four

MediaBot
MSB Article: Mesoblast and Neuren offer new parables for biotech investment

StockBot
MSB Ann: Change of Director's Interest Notice

StockBot
MSB Ann: Mesoblast Director Appointed to Strategic Advisory Role

StockBot
MSB Ann: MSB Reports Q3 Financial Results and Operational Highlights

StockBot
MSB Ann: Third Quarter Results Presentation

StockBot
MSB Ann: Third Quarter Financial Results on Form 6-K

StockBot
MSB Ann: Mesoblast Third Quarter Financial Results Webcast

StockBot
MSB Ann: Becoming a substantial holder

StockBot
MSB Ann: Change in substantial holding

StockBot
MSB Ann: Cleansing Notice

StockBot
MSB Ann: Application for quotation of securities - MSB

StockBot
MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
MSB Ann: Reinstatement to Official Quotation

StockBot
MSB Ann: Proposed issue of securities - MSB

StockBot
MSB Ann: Mesoblast Completes Private Placement

StockBot
MSB Ann: Voluntary Suspension

MediaBot
MSB Article: Mesoblast rattles the tin for at least $37m, Bell Potter in tow

StockBot
MSB Ann: Trading Halt

StockBot
MSB Ann: Pause in Trading

MediaBot
MSB Article: ASX jumps 0.9pc in biggest daily jump in two months

MediaBot
MSB Article: ASX jumps 0.9pc in biggest daily jump in two months

StockBot
MSB Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection

StockBot
MSB Ann: Appendix 3G and Appendix 3H

StockBot
MSB Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

StockBot
MSB Ann: Pause in Trading

StockBot
MSB Ann: Prospectus for Warrants Related to Oaktree Facility

StockBot
MSB Ann: DREAM HF Trial Published in JACC

StockBot
MSB Ann: MSB Q2 Financial Results and Operational Highlights

StockBot
MSB Ann: Second Quarter Results Presentation

StockBot
MSB Ann: Half Yearly Report and Accounts

StockBot
MSB Ann: Mesoblast Second Quarter Financial Results Webcast

StockBot
MSB Ann: Remestemcel Clinical and Potency Studies Presented at Tandem

StockBot
MSB Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP

StockBot
MSB Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD

StockBot
MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
MSB Ann: Appendix 3G, Appendix 3H and Appendix 3Ys

StockBot
MSB Ann: Biotech Showcase 2023 Presentation in San Francisco

MediaBot
MSB Article: Mesoblast receives $US30m debt extension

StockBot
MSB Ann: Extension of Undrawn US$30 million Facility

StockBot
MSB Ann: Proposed issue of securities - MSB

Register to track MSB and receive email alerts.

Similar Companies

CSL ...
CSL
Clinuvel Pharmaceuticals
CUV
Immutep
IMM
Imugene
IMU
Opthea
OPT
Paradigm Biopharmaceuticals
PAR
PYC Therapeutics
PYC
Race Oncology
RAC
Telix Pharmaceuticals
TLX